

GPTHEALTH/CS/SE/2023-24

March 19, 2024

<b>The Department of Corporate Services</b> BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 <b>Scrip Code: 544131</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 <b>Scrip Symbol: GPTHEALTH</b>
---	--

Dear Sir/Madam

**Sub: Outcome of Board Meeting held on March 19, 2024.**

Pursuant to Regulations 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 herein referred as “SEBI (LODR) Regulations, 2015”, the Board of Directors of the Company at their meeting held today i.e. March 19, 2024, has considered, approved and taken on record among other matters: -

1. the Unaudited Financial Result along with Limited Review Report of the Statutory Auditors thereon of the Company for the Quarter & Nine Months ended December 31, 2023;

Further, as required by Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Financial Result along with the Limited Review Report of the Statutory Auditors thereon is enclosed herewith for your record and reference.

The said result will be duly published in the newspaper as required by Regulation 47 of the SEBI (LODR) Regulations, 2015 and will also be uploaded on the website of the company at <https://www.ilshospitals.com>

2. Declaration of Second Interim Dividend @ 10% (₹ 1 per equity share) for the Financial Year 2023-24. The Board has fixed Monday, April 01, 2024 as the “Record Date” to ascertain the names of the shareholders / beneficial owners of the Company to whom the aforesaid interim dividend shall be payable.
3. In compliance with Regulation 30(5) of the SEBI (LODR) Regulations, we have also enclosed the contact details of the Key Managerial Personnel of the Company who have been severally authorized by the Board of Directors at their meeting held today for determining materiality of any event or information and for the purpose of making necessary disclosures to the Stock Exchanges-enclosed as **Annexure A**.
4. Appointment of Dr. Vishal Goyal as Group Chief Operating Officer to be considered as Senior Management Personnel of the Company w.e.f April 1, 2024 as recommended by the Nomination and Remuneration Committee. The brief details as required under Regulation 30 read with Schedule III Part A of Securities and Exchange Board of India (LODR) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 enclosed as **Annexure B**.

We request you to kindly treat aforesaid communication in this letter in compliance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 2:30 P.M and concluded at 3:30 P.M.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

**For GPT Healthcare Limited**

**Ankur Sharma**  
**Company Secretary and Compliance Officer**  
**M. No A31833**

**ANNEXURE A**

Contact details of the Key Managerial Personnel In compliance with Regulation 30(5) of the SEBI (LODR) Regulations for determining materiality of any event or information and for the purpose of making necessary disclosures to the Stock Exchanges:

<b>S. No</b>	<b>Name of the Key Managerial Personnel</b>	<b>Designation</b>	<b>Contact No</b>	<b>Email Id</b>
1	Mr. Anurag Tantia	Executive Director (KMP)	033-4050-7000	anurag@gptgroup.co.in
2	Mrs. Kriti Tantia	Chief Financial Officer (KMP)	033-4050-7000	kriti@gptgroup.co.in
3	Mr. Ankur Sharma	Company Secretary and Compliance Officer (KMP)	033-4050-7000	ghl.cosec@gptgroup.co.in

**ANNEXURE B**

**Details required under Regulation 30 read with Schedule III Part A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015:**

Name of SMP	Dr. Vishal Goyal
Reason for change, viz., appointment, resignation, removal, death or otherwise	Appointed as Group Chief Operating Officer to be considered as Senior Management Personnel of the Company.
Date of appointment/cessation (as applicable) & term of appointment	w.e.f April 1, 2024
Brief profile (in case of appointment)	Dr. Vishal Goyal has a Masters degree in Hospital Administration and also has a MBBS Degree with an experience of 25 years as a healthcare professional. He has been a medical administrator handling operations at individual hospital units at various chains in the country, having experience in managing hospitals with different business models, cultures and geography.
Relationship with Directors	The SMP is not related to any of the Directors of the Company

**Independent Auditor's Review Report on Unaudited Financial Results of GPT Healthcare Limited for the quarter and nine months ended December 31, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
**The Board of Directors**  
**GPT Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results ("the statement) of **GPT Healthcare Limited** ("the Company") for the quarter and nine months ended December 31, 2023. The statement is being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("The Regulation") and has been initialed by us for identification purpose.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors in their meeting held on March 19, 2024, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is drawn to Note 2 of the Statement which states that the figures for the quarter ended September 30, 2023 and corresponding quarter and nine months ended December 31, 2022, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review by the statutory auditor of the Company since the requirement of submission of the quarterly results is applicable on listing of the equity shares of the Company from the quarter ended December 31, 2023.

Further, the figures for the year ended March 2023 have been extracted from the audited standalone financial statement which were prepared in accordance with the requirements of Companies Act, 2013 and audited by us and on which we had issued our unmodified opinion vide our report dated June 20, 2023.

Our conclusion is not modified in respect of above matters.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ('Ind AS') specified under section 133, of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**For Singhi & Co.**  
**Chartered Accountants**  
**Firm Registration No. 302049E**  
NAVINDRA  
KUMAR SURANA  
Digitally signed by NAVINDRA  
KUMAR SURANA  
Date: 2024.03.19 15:22:46  
+05'30'  
**(Navindra Kumar Surana)**  
**Partner**  
**Membership No. 053816**  
**UDIN: 24053816BKACCA2212**

**Place: Kolkata**  
**Date: March 19, 2024**

# GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India  
CIN : U70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in



## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED DECEMBER 31, 2023

₹ in lakhs (except per share data)

Particulars	Quarter Ended			Nine months period ended		Year ended
	31-Dec-23 (Unaudited)	30-Sep-23 (Refer Note-2)	31-Dec-22 (Refer Note-2)	31-Dec-23 (Unaudited)	31-Dec-22 (Refer Note-2)	31-Mar-23 (Audited)
<b>1 INCOME</b>						
(a) Revenue from operations	9,659.17	10,797.51	9,298.72	30,076.73	26,495.41	36,103.71
(b) Other income	117.82	108.72	85.51	369.92	336.17	569.36
<b>Total Income</b>	<b>9,776.99</b>	<b>10,906.23</b>	<b>9,384.23</b>	<b>30,446.65</b>	<b>26,831.58</b>	<b>36,673.07</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	1,969.56	2,238.87	1,911.85	6,217.42	5,555.45	7,586.34
(b) Employee benefits expense	1,726.21	1,744.23	1,563.32	5,193.72	4,709.18	6,203.79
(c) Finance costs	169.05	181.44	228.49	551.10	664.29	916.39
(d) Depreciation and amortisation expense	450.11	438.54	394.62	1,322.32	1,087.17	1,491.23
(e) Other expenses	3,863.31	4,354.55	3,788.13	12,199.18	11,153.60	14,878.38
<b>Total Expenses</b>	<b>8,178.24</b>	<b>8,957.63</b>	<b>7,886.41</b>	<b>25,483.74</b>	<b>23,169.69</b>	<b>31,076.13</b>
<b>3 Profit before Tax (1-2)</b>	<b>1,598.75</b>	<b>1,948.60</b>	<b>1,497.82</b>	<b>4,962.91</b>	<b>3,661.89</b>	<b>5,596.94</b>
<b>4 Tax expense</b>						
a) Current tax	282.00	340.00	261.00	869.00	639.00	975.00
b) Deferred tax (including MAT Credit entitlement)	169.75	258.30	401.42	598.64	489.00	722.64
c) Income tax for earlier year	-	-	-	-	-	(1.46)
<b>Total Tax expenses</b>	<b>451.75</b>	<b>598.30</b>	<b>662.42</b>	<b>1,467.64</b>	<b>1,128.00</b>	<b>1,696.18</b>
<b>5 Profit for the period (5-4)</b>	<b>1,147.00</b>	<b>1,350.30</b>	<b>835.40</b>	<b>3,495.27</b>	<b>2,533.89</b>	<b>3,900.76</b>
<b>6 Other Comprehensive Income</b>						
<u>A. Items that will not be reclassified to profit or loss</u>						
a) Remeasurement of defined benefit plan	(10.00)	5.04	11.30	(40.27)	11.40	18.93
b) Income tax relating to above	2.92	(1.46)	(3.29)	11.74	(3.32)	(5.52)
<u>B. Items that will be reclassified to profit or loss</u>	-	-	-	-	-	-
<b>Other Comprehensive Income for the period</b>	<b>(7.08)</b>	<b>3.58</b>	<b>8.01</b>	<b>(28.53)</b>	<b>8.08</b>	<b>13.41</b>
<b>7 Total Comprehensive Income for the period (5+6)</b>	<b>1,139.92</b>	<b>1,353.88</b>	<b>843.41</b>	<b>3,466.74</b>	<b>2,541.97</b>	<b>3,914.17</b>
<b>8 Paid up equity share capital (face value of ₹ 10 each)</b>	799.04	799.04	799.04	799.04	799.04	799.04
<b>9 Other Equity</b>						854.58
<b>11 Earnings per equity share (of Rs. 10 each) :</b>						
(a) Basic (Rs.)	1.44 *	1.69 *	1.05 *	4.37 *	3.17 *	4.88
(b) Diluted (Rs.)	1.44 *	1.69 *	1.05 *	4.37 *	3.17 *	4.88
* Not annualized						

NAVINDRA  
KUMAR  
SURANA

Digitally signed by  
NAVINDRA KUMAR  
SURANA  
Date: 2024.03.19  
15:24:02 +05'30'

**DWARIKA  
PRASAD  
TANTIA** Digitally signed by  
DWARIKA PRASAD  
TANTIA  
Date: 2024.03.19  
15:16:31 +05'30'

Notes:

- 1 This statement have been prepared in accordance with the recognition and measurements principles as laid down in Indian Accounting Standard ("Ind AS") 34 - "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on March 19, 2024. The said results have subject to limited review by the statutory auditors of the company for the quarter and nine months December 31, 2023. The financial results for the quarter and nine months ended December 31, 2022 and for the quarter ended September 30, 2023 have not been reviewed / audited by the statutory auditors. The management has exercised necessary diligence to ensure that the financial results for the periods provide a true and fair view of the Company's affairs.
- 3 GPT Healthcare Limited ("the Company") has completed Initial Public Offering (IPO) comprising of fresh issue of 21,50,537 equity shares and offer for sale from investor selling shareholder of 2,60,82,786 equity shares of face value ₹10 each at an issue price of ₹186 per share for cash consideration aggregating to ₹525.14 Crores, subsequent to quarter ended December 31, 2023. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange w.e.f. February 29, 2024. The above statement of unaudited financial results for the quarter and nine months ended December 31, 2023 are drawn up in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 4 The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India.
- 5 The Board of Directors of the Company have declared a second Interim Dividend @ 10% i.e. ₹1 per Equity Share. The record date for payment of second interim dividend has been fixed as April 1, 2024. Total dividend for the financial year 2023-24 is ₹2 per Equity share on the face value of ₹10 per share.
- 6 The above unaudited financial results are also available on the Company's website [www.ilshospitals.com](http://www.ilshospitals.com) and also on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).

NAVINDRA  
KUMAR  
SURANA

Digitally signed by  
NAVINDRA KUMAR  
SURANA  
Date: 2024.03.19  
15:24:37 +05'30'

For and on behalf of the Board

DWARIKA  
PRASAD TANTIA

Digitally signed by  
DWARIKA PRASAD TANTIA  
Date: 2024.03.19 15:16:55  
+05'30'

Dwarika Prasad Tantia  
Chairman and Whole Time Director  
DIN: 00001341

Place : Kolkata

Date : March 19, 2024